Piramal Pharma approves grant of 56.3 lakh stock options

2 min read     Updated on 29 Jul 2026, 06:36 PM
scanx
Reviewed by
Ashish TScanX News Team
AI Summary

Piramal Pharma Limited's Nomination and Remuneration Committee approved the grant of 56,36,436 stock options under the 2022 ESOP plan on July 29, 2026. Priced at ₹10 per option, the grants feature distinct vesting schedules for domestic and US employees, with vesting periods spanning up to three years. The move complies with SEBI Listing Regulations and aims to align employee interests with long-term shareholder value.

powered bylight_fuzz_icon
46875946

*this image is generated using AI for illustrative purposes only.

Piramal Pharma Limited Piramal Pharma Limited has approved the grant of 56,36,436 stock options to its employees under the Employee Stock Option and Incentive Plan 2022. The Nomination and Remuneration Committee of the Board of Directors sanctioned the grants during its meeting held on July 29, 2026, in accordance with Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The total number of equity shares covered by these options stands at 56,36,436. Each option carries an exercise price of ₹10 per option. This pricing structure is designed to provide employees with a fixed cost basis for acquiring shares, potentially offering upside participation if the market price exceeds the exercise price over the vesting period.

Vesting and Exercise Terms

The vesting schedule varies depending on the employee's location, specifically distinguishing between staff based outside the United States and those within the US. For all locations except the US, three alternative vesting structures apply:

Vesting Tranche Vesting Date Exercisable Until Applicable Structure
1/3rd July 29, 2027 July 28, 2032 Option A
1/3rd July 29, 2028 July 28, 2033 Option A
1/3rd July 29, 2029 July 28, 2034 Option A
2/3rd July 29, 2027 July 28, 2032 Option B
1/3rd July 29, 2028 July 28, 2033 Option B
70% July 29, 2027 July 28, 2032 Option C
30% July 29, 2028 July 28, 2033 Option C

For employees located in the US, the vesting schedule is more accelerated, with all tranches becoming exercisable within a shorter window after vesting:

Vesting Tranche Vesting Date Exercisable Until
1/3rd July 29, 2027 March 15, 2028
1/3rd July 29, 2028 March 15, 2029
1/3rd July 29, 2029 March 15, 2030

Options can generally be exercised within five years commencing from the date of vesting of each tranche. However, for US-based employees, the exercise period is strictly limited to the dates mentioned in the schedule above.

Regulatory Compliance

The disclosure was made pursuant to Regulation 30 read with Schedule III to the SEBI Listing Regulations. The scheme is compliant with the SEBI (Share Based Employee Benefits) Regulations, 2021. Maneesh Sharma, Company Secretary & Compliance Officer, signed the filing submitted to both BSE Limited and the National Stock Exchange of India Limited on July 29, 2026.

Historical Stock Returns for Piramal Pharma

1 Day5 Days1 Month6 Months1 Year5 Years
+1.16%+5.88%+17.37%+27.10%-4.24%+5.46%

How might the dilution from 56.36 lakh new equity shares impact Piramal Pharma's earnings per share (EPS) and existing shareholder value over the next five years?

Given the low exercise price of ₹10, what is the estimated total share-based compensation expense this grant will add to the company's P&L in the upcoming fiscal years?

Will the accelerated vesting schedule for US-based employees signal a strategic push to retain talent in key Western markets amidst rising global pharmaceutical competition?

Piramal Pharma Records ₹18.10 Crore Block Trade on NSE at ₹196.12 Per Share

0 min read     Updated on 29 Jul 2026, 11:51 AM
scanx
Reviewed by
ScanX News Team
AI Summary

Piramal Pharma recorded a block trade on the NSE valued at ₹18.10 crores, involving approximately 923,070 shares at ₹196.12 per share. Block trades of this magnitude are generally associated with institutional investor activity. The transaction highlights notable large-scale participation in the Piramal Pharma counter on the NSE.

powered bylight_fuzz_icon
46851653

*this image is generated using AI for illustrative purposes only.

Piramal Pharma witnessed a notable block trade on the National Stock Exchange (NSE), with a transaction valued at ₹18.10 crores. The trade involved approximately 923,070 shares, executed at a price of ₹196.12 per share, signalling significant institutional participation in the counter.

Block Trade Details

The following table summarises the key parameters of the block trade recorded on the NSE:

Parameter: Details
Exchange: NSE
Trade Value: ₹18.10 crores
Number of Shares: ~923,070
Trade Price: ₹196.12 per share

Significance of Block Trades

Block trades are large-volume transactions typically executed by institutional investors such as mutual funds, foreign portfolio investors, or other large entities. Such trades are conducted outside the regular market order book to minimise price impact and are closely tracked by market participants as indicators of institutional interest in a particular stock.

Historical Stock Returns for Piramal Pharma

1 Day5 Days1 Month6 Months1 Year5 Years
+1.16%+5.88%+17.37%+27.10%-4.24%+5.46%

Who was the institutional buyer or seller in this ₹18.10 crore block trade, and does their identity signal a shift in long-term sentiment?

How might this large-volume transaction at ₹196.12 influence Piramal Pharma's short-term technical support and resistance levels?

Is this block trade indicative of broader foreign portfolio investor (FPI) activity in the Indian pharmaceutical sector amid current global market volatility?

More News on Piramal Pharma

1 Year Returns:-4.24%